 SAN DIEGO--BUSINESS WIRE--Odonate Therapeutics, Inc. NASDAQ: ODT, a pharmaceutical company dedicated to the development of bestinclass therapeutics that improve and extend the lives of patients with cancer, today announced that positive results from CONTESSA, a Phase 3 study of tesetaxel in patients with metastatic breast cancer MBC, were presented in an oral presentation at the 2020 San Antonio Breast Cancer Symposium SABCS. The results were presented by Joyce OShaughnessy, M.D., Ce 